|1.||Blitterswijk, Wim J van: 1 article (05/2014)|
|2.||Verheij, Marcel: 1 article (05/2014)|
|3.||Moolenaar, Wouter H: 1 article (05/2014)|
|4.||O'Dwyer, Peter J: 1 article (02/2004)|
|5.||Derry, Christine: 1 article (02/2004)|
|6.||Giantonio, Bruce J: 1 article (02/2004)|
|7.||McAleer, Cecilia: 1 article (02/2004)|
|8.||McPhillips, Joseph J: 1 article (02/2004)|
02/15/2004 - "A Phase I trial was performed to determine the dose-limiting toxicity and maximum tolerated dose, and to describe the pharmacokinetics of the alkyl-lysophospholipid, ilmofosine, when administered as a weekly 2-h infusion in patients with solid tumors. "
01/01/1997 - "The thioether phospholipid ilmofosine (BM 41 440) is a new anti-cancer drug presently undergoing phase II clinical trials. "
02/01/1992 - "Clinical phase II trials with ilmofosine including the tumor types with in vitro sensitivity are warranted if adequate plasma concentrations of this agent can be reached in patients."
11/01/1987 - "BM 41.440 was evaluated in a multicenter phase I study in patients (pts) with refractory cancers. "
11/01/1987 - "Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients."
01/01/1996 - "A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma."
01/01/1996 - "We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. "
12/01/1988 - "Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells."
11/01/1987 - "Screening for cytotoxicity in the clonogenic assay in human tumor xenografts and L1210 mouse leukemia revealed comparable dose-dependent effects of the alkyl lysophospholipid ET-18-OCH3 and the thioether lipid BM 41.440. "
11/01/1987 - "The effects of 2-lysophosphatidylcholine (2-LPC), the alkyl lysophospholipid derivatives (ALP) 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) and 1-O-hexadecyl-sn-glycero-3-phospho-trimethyl-ammonio-hexanol, the 2-acetamide analog of platelet-activating factor (PAF) 1-O-octadecyl-2-acetamide-sn-glycero-3-phosphocholine, the thioether lysophospholipid derivative (TLP) BM 41.440 and the ether-linked lipoidal amine CP-46,665 on tritiated thymidine uptake and trypan blue dye exclusion were tested in vitro in various freshly explanted cell samples from human nonneoplastic bone marrow and human leukemias. "
|5.||Neoplasm Metastasis (Metastasis)
01/01/1992 - "We thus conclude that treatment with oral ilmofosine is not effective in patients with liver metastases due to various malignancies."
12/01/1991 - "Ilmofosine caused a significant dose-related response on tumor growth and metastases, expressed in terms of tumor diameter, tumor weight, survival time and number of metastases-free animals as compared to sham-treated and positive (cyclophosphamide) controls. "
|1.||Ethyl Ether (Ether)
|9.||Protein Kinase C
|10.||Platelet Activating Factor
|1.||Heterologous Transplantation (Xenotransplantation)